Regulation
The Cannabis Sector and Its Dot-Com Like Meltdown
Black-market vaping has made the entire cannabis group toxic.
Have Those Once-Smoking Cannabis Stocks Burnt Down to a Bottom?
Several watchers and market players are deep in the weeds, tracking short action and key companies like Canopy Growth, trying to find out whether the industry has turned over a new leaf.
These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Why Macy's Is at Risk of Losing Its Shirt
Earnings misses, bad planning, and product-line execution problems are all hitting the retailer, but it's the macro woes that will also hurt its competitors.
Earnings to Tell Whether Cannabis' High Growth Story Is Going to Pot
After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.
A Look at Mylan's New Post-Merger Management
What new management means for Mylan shareholders moving forward.
Mylan Jumps on Deal With Pfizer to Form New Company
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Alphabet Shares Soar After Excellent Earnings Results
A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.
Tesla Tanks as Profitability Problems Persist, Another Executive Exits
Volatility reigns once again at the electric carmaker, which is seeing JB Straubel depart as chief technology officer.
Interesting Small-Cap Charts Are Developing Into Earnings
Big-cap names have been driving the market, but some small-caps could make noise, too.
Feds Probe Tech, Mueller Speaks, Holy Guacamole and Now Hear NOW: Market Recon
Watch closely as the government opens a broad antitrust investigation into unidentified leading online technology platforms
CannTrust Is Caught in a Cannabis Catch-22
The loss of clients is a primary concern here.
What Trump's Bank Charter Challenge Means for Facebook's Libra
It is unclear how a 'libra' denominated transaction might be governed in the future and it might require the creation of an entirely new oversight entity.
Facebook Falters Amid Political Pressure on Libra Digital Currency
Surprise, surprise: Regulatory opposition toward digital currencies at home and abroad is rising against Facebook.
Deutsche Bank Stock Declines as Transformation Plan Sinks In
Deutsche is looking to drop the "bad bank" moniker with big moves on Monday.
2 Attractive Biotechs With Key Study Outcomes on the Horizon
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
Boeing Loses Altitude as FAA Finds More Risks Related to 737 MAX
The Federal Aviation Administration has declined to set a timeline on when it will lift its order prohibiting the troubled aircraft from flying.
Trump-Xi Face Off, Potential EU Land Mines and a Caterpillar Play: Market Recon
The G-20 Summit in Japan could hold more intrigue than just the planned meeting between President Trump and Xi.
Micron's Surge Causes Skeptics to Step Back
A number of vocal analysts and investors are calling for caution on those eager to buy the semiconductor stock amidst its Wednesday morning leap.
Micron's Unexpected Move Higher Boosts Semiconductor Sentiment
Micron is motivating more positive outlook on the semiconductor sector's road ahead.
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Charts of the Day: The States of U.S. Gambling
A bit of context to simmer on following the big deal between Caesars and Eldorado.
Prohibition and the Paradoxical Proclivity of Cannabis Consumption
Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?
Can Oracle Retake Lost Market Share -- Or Is It In the Clouds?
Oracle tells investors it can regain the crown it once held among enterprises and end-users, but some aren't so sure.
Wall Street Is Still Waiting on the Oracle Debate to Settle
Is the bad news for Oracle all over?
Tencent-Backed WeDoctor Scraps International Listing for Shanghai
The healthcare app creator reportedly shelves a Hong Kong listing in favor of "China's Nasdaq" due to data privacy and transparency concerns.